We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor‑alfa Antagonists for the Treatment of Inflammatory Bowel Disease.
- Authors
Mosli, Mahmoud H.; Al‑Harbi, Othman; Feagan, Brian G.; Almadi, Majid A.
- Abstract
The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor‑alfa (TNF‑α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF‑α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents.
- Subjects
SAUDI Arabia; INFLIXIMAB; ADALIMUMAB; GOLIMUMAB; ALGORITHMS; COMBINATION drug therapy; CROHN'S disease; GASTROINTESTINAL diseases; INFLAMMATORY bowel diseases; MEDICAL protocols; RISK assessment; SAFETY; TUMOR necrosis factors; ULCERATIVE colitis; SOCIAL services case management; CHEMICAL inhibitors; THERAPEUTICS
- Publication
Saudi Journal of Gastroenterology, 2015, Vol 21, Issue 4, p185
- ISSN
1319-3767
- Publication type
Article
- DOI
10.4103/1319-3767.161635